COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS

被引：0
|
作者：
Ortonne, J. P. [1 ]
Feneron, D. [2 ]
Daures, J. P. [3 ]
Ollivier, A. L. [4 ]
Thiriet, C. [4 ]
Maurel, F. [2 ]
Le Pen, C. [5 ]
机构：
[1] Hop Archet 2, Nice, France
[2] IMS Hlth, Puteaux La Defense, France
[3] CHU Nimes, Nimes, France
[4] Wyeth Pharmaceut, Paris, France
[5] Univ Paris 09, Paris, France
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67017-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A617 / A617
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of apremilast in moderate to severe psoriasis in the UK
    Mughal, Farhan
    Barker, Jonathan
    Cawston, Helene
    Damera, Vidya
    Bewley, Anthony
    Morris, James
    Shaw, Tim
    Tencer, Tom
    Zhang, Frank
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB243 - AB243
  • [22] Cost-effectiveness of treatment for moderate-to-severe psoriasis
    Hankin, CS
    Feldman, SR
    Pearce, D
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 654 - 654
  • [23] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [24] COST-EFFECTIVENESS OF BIOLOGIC TREATMENTS FOR MODERATE TO SEVERE PSORIASIS
    Carretero, G.
    Moreno, J. C.
    Notario, J.
    Silvestre, J. F.
    Lopez-Belmonte, J. L.
    Gimenez, E.
    Sabater, F. J.
    Fonseca, E.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A457 - A457
  • [25] Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis
    Papp, KA
    Miller, B
    Gordon, KB
    Caro, I
    Kwon, P
    Compton, PG
    Leonardi, CL
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (04) : S164 - S170
  • [26] Efalizumab A Review of its Use in the Management of Chronic Moderate-to-Severe Plaque Psoriasis
    Frampton, James E.
    Plosker, Greg L.
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2009, 10 (01) : 51 - 72
  • [27] Cost-effectiveness of apremilast in moderate-to-severe chronic plaque psoriasis: a model analysis in the UK
    Mughal, F.
    Barker, J.
    Cawston, H.
    Damera, V.
    Bewley, A.
    Morris, J.
    Shaw, T.
    Tencer, T.
    Zhang, F.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 74 - 74
  • [28] COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB COMPA RED WITH ETANERCEPT FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COSTA RICA
    Obando, C. A.
    Desanvicente-Celis, Z.
    Herrera, J. A.
    Moreira, M.
    De Castro, J.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A607 - A607
  • [29] Efficacy and safety of etanercept in moderate to severe plaque psoriasis
    Tunca, M.
    Koc, E.
    Akar, A.
    Kurumlu, Z.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 : 53 - 53
  • [30] Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
    Villacorta, Reginald
    Hay, Joel W.
    Messali, Andrew
    [J]. PHARMACOECONOMICS, 2013, 31 (09) : 823 - 839
12345